DB17565InvestigationalVaccines
Polyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant keyhole limpet... It is under investigation in clinical trial NCT01223235 (Polyvalent Vaccine-klh Conjugate + Opt-821 Given in Combination With Bevacizumab).
What you can answer from here — as of April 23, 2025
Which companies are running trials of Polyvalent antigen-KLH conjugate vaccine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account